Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BPTES||bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide||Glutaminase Inhibitor 3||BPTES is a small molecule that inhibits glutaminase, which results in decreased conversion of glutamine to glutamate, and potentially leads to decreased tumor cell growth (PMID: 21045145, PMID: 25915584, PMID: 32450839).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|VHL loss||renal cell carcinoma||sensitive||BPTES||Preclinical - Cell culture||Actionable||In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).||28346230|
|IDH1 R132H||high grade glioma||sensitive||BPTES||Preclinical - Cell culture||Actionable||In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).||21045145|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|